Novo Nordisk's Clinical Win and Competitive Crossroads

Novo Nordisk's etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23% YTD on 2026 revenue warnings and GLP-1 competition.

Novo Nordisk shares, trading at 34.48 EUR, have shed roughly 23 percent since the start of the year, a stark decline that places them about 50 percent below their 52-week high. This pressure stems from a challenging outlook: the company forecasts a 5 to 13 percent drop in revenue at constant exchange rates for 2026, citing U.S. pricing pressures, reduced Medicaid coverage for obesity drugs, and the "Most Favoured Nations" pricing agreement. Yet, against this grim financial backdrop, the Danish pharmaceutical giant has just secured a significant clinical victory.

The company announced that its Phase 3 HIBISCUS trial for the drug etavopivat in sickle cell disease successfully met both co-primary endpoints. This outcome is notable for a first-in-class mechanism. The study, involving 385 participants aged 12 and older, showed etavopivat—taken once daily orally alongside standard therapy—reduced vaso-occlusive crises by 27 percent compared to placebo. The median time to a first crisis event was 38.4 weeks versus 20.9 weeks in the control group. The hemoglobin response was even more pronounced, with nearly 49 percent of patients on etavopivat achieving an increase of more than 1 g/dL after 24 weeks, compared to just 7.2 percent on placebo.

This asset, acquired through the 2022 takeover of Forma Therapeutics, is designed to bolster Novo Nordisk's presence in hemoglobinopathies and diversify its portfolio. Etavopivat holds Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S., along with Orphan Drug status in the EU. The company plans to submit its first regulatory application in the second half of 2026. To strengthen the filing package, a follow-up study, HIBISCUS2, is underway with 408 participants, directly testing etavopivat against standard therapy. The full HIBISCUS data set is slated for presentation at a scientific conference later this year.

While advancing in rare disease, Novo Nordisk faces intensified competition in its core market. Rival Eli Lilly has ended Novo's brief monopoly in the oral GLP-1 space with the U.S. launch of Foundayo (orforglipron) in April. In response, Novo has pointed to cross-trial data comparing its oral Wegovy pill to Lilly's candidate. Over 64 weeks, oral Wegovy demonstrated 13.6 percent weight loss, while orforglipron showed 11.2 percent over 72 weeks. Novo also highlights a stark difference in discontinuation rates due to side effects, which were approximately 14 times higher with orforglipron. The company argues its safety profile is more established, as oral Wegovy uses the same molecule as the injectable version, which has been on the market for years.

Internally, a corporate restructuring continues. After cutting about ten percent of its workforce in 2025, CEO Mike Doustdar has overseen the hiring of around 2,000 new employees, with roughly 1,400 already onboard. The total headcount remains stable at approximately 69,500, aided by an annual natural turnover rate of about five percent. The new hires are focused on production, research, and commercial operations. This reshuffle, however, has seen the departure of key talent, including Lotte Bjerre Knudsen, a scientist instrumental in developing the GLP-1 therapies.

Financially, the company is executing a share buyback program of up to 15 billion Danish kroner over twelve months. By April 10, it had repurchased over 11 million B shares at an average price of 257.56 DKK, for a total transaction value of nearly 2.84 billion DKK.

All eyes now turn to the first-quarter results due in May. These figures will indicate whether the stock's steep decline has fully accounted for the lowered annual guidance or if more downside is ahead. A critical factor will be the early prescription uptake of Lilly's Foundayo, which will test the resilience of Novo Nordisk's market position even as it celebrates a hard-won clinical success.